Angel Tejido-Sánchez

Dr. Angel Tejido-Sánchez


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2017 in Urologia Internationalis
Verified
Journal Article
Closed access
ALAlba Lara-Isla
Alba Lara-Isla
JMJosé Medina-Polo
José Medina-Polo
MAManuel Alonso-Isa
Manuel Alonso-Isa
RBRaúl Benítez-Sala
Raúl Benítez-Sala
RSRaquel Sopeña-Sutil
Raquel Sopeña-Sutil
ATAngel Tejido-Sánchez
Angel Tejido-Sánchez
Background: Infections related to catheters in the upper urinary tract (CUUT) are associated with specific characteristics. Methods: A prospective observational study was carried out from 2012 to 2015 to evaluate infections in patients with CUUT. Results: A total of 209 infections were included (99 with double-J, 81 with nephrostomy, and 29 with internal/external nephroureteral stents). Among nephrostomy tube carriers, the most frequently isolated microorganisms were Pseudomonas and Enterococcus. In those with an internal/external nephroureteral stent, Klebsiella was the most common, and 57.1% were extended-spectrum beta-lactamase-producing Klebsiella. In double-J carriers, Escherichia coli and Enterococcus were the most common microorganisms. Multiple-drug resistance (MDR) microorganisms were isolated in 28.6, 47.1, and 58.3% of patients with double-J, nephrostomy, and internal-external nephroureteral stents. A percutaneous CUUT (p = 0.005) and immunosuppression (p = 0.034) were risk factors for MDR microorganisms. Conclusions: Non-E. coli bacteria are commonly isolated in patients with CUUT. MDR microorganisms are frequent, mainly in percutaneous approach or immunosuppression.

1 January 2017 in Investigative and Clinical Urology
Verified
Journal Article
Open access
JMJosé Medina-Polo
José Medina-Polo
RSRaquel Sopeña-Sutil
Raquel Sopeña-Sutil
RBRaúl Benítez-Sala
Raúl Benítez-Sala
ALAlba Lara-Isla
Alba Lara-Isla
MAManuel Alonso-Isa
Manuel Alonso-Isa
ATAngel Tejido-Sánchez
Angel Tejido-Sánchez
Healthcare-associated infections (HAIs) in urological patients have special features due to specific risk factors. Our objective was to evaluate the characteristics and risk factors for HAIs in patients hospitalized in a Urology ward. We evaluated prospectively, from 2012 to 2015, the incidence, types and risk factor for HAIs, microbiological and resistance patterns. The incidence of HAIs was 6.3%. The most common types were urinary infections (70.5%) and surgical site infections (22.1%). Univariate analysis showed an increased risk of HAIs among patients with American Society of Anesthesiologists physical status classification system III-IV (odds ratio [OR], 1.39; p<0.001), immunosuppression (OR, 1.80; p=0.013), previous urinary infection (OR, 4.46; p<0,001), and urinary catheter before admission (OR, 1.74; p<0.001). The surgical procedures with the highest incidence of HAIs were radical cystectomy (54.2%) and renal surgery (8.7%). The most frequently isolated microorganisms were Escherichia coli (25.1%), Enterococcus spp. (17.5%), Klebsiella spp. (13.5%) and Pseudomonas aeruginosa (12.3%). Enterococcus sp was the most common microorganism after radical cystectomy and in surgical site infections, E. coli showed resistance rates of 53.5% for fluoroquinolones, 9.3% for amikacin. The percentage of extended-spectrum betalactamase producing E. coli was 24.7%. Klebsiella spp. showed resistance rates of 47.8% for fluoroquinolones, 7.1% for amikacin and 4.3% for carbapenems. Enterococcus spp showed resistance rates of 1.7% for vancomycin and; P. aeruginosa of 33.3% for carbapenems and 26.2% for amikacin. Comorbidities, previous urinary infections, and urinary catheter are risk factors for HAIs. The microorganisms most commonly isolated were E. coli, Enterococcus and P. aeruginosa. Prospective monitoring may decrease the incidence of infections.

23 September 2015 in Urologia Internationalis
Verified
Journal Article
Closed access
PDF file
JMJosé Medina-Polo
José Medina-Polo
AAAna Arrébola-Pajares
Ana Arrébola-Pajares
SPSantiago Pérez-Cadavid
Santiago Pérez-Cadavid
RBRaúl Benítez-Sala
Raúl Benítez-Sala
RSRaquel Sopeña-Sutil
Raquel Sopeña-Sutil
ATAngel Tejido-Sánchez
Angel Tejido-Sánchez
Introduction: Our aim was to describe the incidence and risk factors associated with extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and their resistance rate in a urological ward. Material and Methods: We carried out a prospective observational study from November 2011 to December 2014, reviewing healthcare-associated infections (HAIs) in our department. We evaluated the infections caused by ESBL-producing Enterobacteriaceae. Results: The incidence of HAIs in our urology ward was 6.8%. Enterobacteriaceae including Escherichia coli (24.9%), Klebsiella spp. (12.1%), Enterobacter spp. (5.9%), Morganella spp. (1.5%), Proteus spp. (1.5%), and Citrobacter spp. (1.5%) represented 47.4% of the isolated pathogens. The percentage of ESBL-producing Enterobacteriaceae was 26.4. Risk factors associated with a higher incidence of ESBL-producing bacteria were prior urinary tract infection (UTI; p < 0.001), hypertension (p = 0.042), immunosuppression (p = 0.004), and urinary stone (p = 0.027). The multivariable analysis confirmed prior UTI, immunosuppression and urinary stone as risk factors. ESBL-producing strains showed resistance rates of 85.3% for fluoroquinolones and 11.8% for carbapenems. Moreover, 16.7% of ESBL-Klebsiella were resistant to carbapenems. Conclusions: ESBL-producing enterobacteria are associated with higher cross resistance to antibiotics such as quinolones. Higher resistance rates are reported in ESBL-producing Klebsiella. Among patients admitted in a urology ward, risk factors for ESBL-producing strains were previous UTI, immunosuppression, and urinary stone.

25 April 2022 in Urologia Internationalis
Verified
Journal Article
Closed access
PDF file
RBRocío Santos Pérez de la Blanca
Rocío Santos Pérez de la Blanca
JMJosé Medina-Polo
José Medina-Polo
HPHelena Peña-Vallejo
Helena Peña-Vallejo
SJSilvia Juste-Álvarez
Silvia Juste-Álvarez
MPManuel Pamplona-Casamayor
Manuel Pamplona-Casamayor
ATAngel Tejido-Sánchez
Angel Tejido-Sánchez
Introduction: Ureteral complications after kidney transplantation are frequent and may have a negative impact on morbidity and graft function. Treatment modalities include conservative, endourological, and surgical techniques, with variable outcomes. The purpose of this study was to report the incidence, characteristics, treatment, and outcomes of ureteral complications at our center. Methods: Retrospective study of kidney transplants performed at our unit between 2015 and 2020, analyzing incidence, characteristics, treatment, and outcomes of ureteral stenoses and fistulas. Results: Of 648 kidney transplants, we present 3.24% stenosis and 2.16% ureteral fistulas, with a mean time from transplantation of 101.4 and 24.4 days, respectively. Primary treatment was open surgical repair in 52.4% stenosis and 100% fistulas, with a success rate of 90.9% and 71.4%, respectively. Anterograde balloon dilatations were performed in 33.3% of stenosis with 40% success. Three patients required surgery as a secondary approach with 100% success. Major complications (Clavien-Dindo III) were observed in 18.5% following surgical repair. After a mean follow-up of 31.1 ± 20.9 months, we observe 88.6% of functioning grafts. We found no significant differences in graft survival between patients with or without ureteral complications (p 0.948). Conclusion: Surgical repair of ureteral complications offers satisfactory results with low associated morbidity. Endourological techniques are less effective and should be reserved for selected cases. With adequate management, there is no impact on graft survival.

30 January 2019 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
JMJosé Medina-Polo
José Medina-Polo
JGJavier Gil-Moradillo
Javier Gil-Moradillo
JJJuan Justo-Quintas
Juan Justo-Quintas
DGDaniel Antonio González-Padilla
Daniel Antonio González-Padilla
EREsther García Rojo
Esther García Rojo
ATAngel Tejido-Sánchez
Angel Tejido-Sánchez

23 June 2020 in Actas Urológicas Españolas
Verified
Journal Article
Closed access
ATAngel Tejido-Sánchez
Angel Tejido-Sánchez
AGA. González-Díaz
A. González-Díaz
EGE. García-Rojo
E. García-Rojo
RBR. Santos-Pérez de la Blanca
R. Santos-Pérez de la Blanca
CVC. Varela-Rodríguez
C. Varela-Rodríguez
ARA. Rodríguez-Antolín
A. Rodríguez-Antolín